Potential therapeutic targets for the treatment of inflammatory bowel diseases
Authors:
P. Hlaušková 1,2; K. Urbánek 2
Authors‘ workplace:
II. interní klinika – gastroenterologická a geriatrická LF UP a FN Olomouc
1; Ústav farmakologie LF UP a FN Olomouc
2
Published in:
Gastroent Hepatol 2026; 80(2): 150-158
Category:
doi:
https://doi.org/10.48095/ccgh2026150
Overview
Research and development of new drugs for the treatment of inflammatory bowel diseases focuses on approximately 20 potential pharmacodynamic targets. Most of these are receptors for inflammatory mediators and enzymes involved in their function, as well as cytokines themselves. In addition, influencing micro-RNA, immune checkpoints, or an inflammasome appears to be a potential therapeutic option. The most advanced developments to date are in the areas of TL1A cytokine inhibition, microRNA-124 function stimulation, interleukin 6 trans-signalling pathway inhibition, and the type I transforming growth factor b receptor blockade. However, none of the tested targets appear to be entirely specific to the pathophysiology of inflammatory bowel diseases, which is a prerequisite for the development of potentially curative pharmacotherapy.
Keywords:
inflammatory bowel diseases – pharmacotherapy – pharmacodynamics – therapeutic targets
Sources
1. Ng SC, Shi HY, Hamidi N et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2017; 390(10114): 2769 – 2778. doi: 10.1016/ S0140-6736(17)32448-0.
2. Petronio L, Dal Buono A, Gabbiadini R et al. Drug development in inflammatory bowel diseases: what is next? Pharmaceuticals (Basel) 2025; 18(2): 190. doi: 10.3390/ ph18020190.
3. Valatas V, Kolios G, Bamias G. TL1A (TNFSF15) and DR3 (TNFRSF25): a co-stimulatory system of cytokines with diverse functions in gut mucosal immunity. Front Immunol 2019; 10 : 583. doi: 10.3389/ fimmu.2019.00583.
4. Varricchi G, Poto R, Criscuolo G et al. TL1A, a novel alarmin in airway, intestinal, and autoimmune disorders. J Allergy Clin Immunol 2025; 155(5): 1420 – 1434. doi: 10.1016/
j.jaci.2025.02.018.
5. Solitano V, Jairath V, Ungaro F et al. TL1A inhibition for inflammatory bowel disease treatment: from inflammation to fibrosis. Med 2024; 5(5): 386 – 400. doi: 10.1016/ j.medj.2024.
03.010.
6. Feagan BG, Sands BE, Siegel CA et al. Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn’s disease: a phase 2a induction trial. Lancet Gastroenterol Hepatol 2025; 10(8): 715 – 725. doi: 10.1016/ S2468-1253 (25)00071-8.
7. Sands BE, Feagan BG, Peyrin-Biroulet L et al. Phase 2 trial of anti-TL1A monoclonal antibody tulisokibart for ulcerative colitis. N Engl J Med 2024; 391(12): 1119 – 1129. doi: 10.1056/ NEJM
oa 2314076.
8. Suri K, Bubier JA, Wiles MV et al. Role of microRNA in inflammatory bowel disease: clinical evidence and the development of preclinical animal models. Cells 2021; 10(9): 2204. doi: 10.3390/ cells10092204.
9. Tazi J, Begon-Pescia C, Campos N et al. Specific and selective induction of miR-124 in immune cells by the quinoline ABX464: a transformative therapy for inflammatory diseases. Drug Discov Today 2021; 26(4): 1030 – 1039. doi: 10.1016/ j.drudis.2020.12.019.
10. Sugimoto K. Role of STAT3 in inflammatory bowel disease. World J Gastroenterol 2008; 14(33): 5110 – 5114. doi: 10.3748/ wjg.14.5110.
11. Koukos G, Polytarchou C, Kaplan JL et al. MicroRNA-124 regulates STAT3 expression and is down-regulated in colon tissues of pediatric patients with ulcerative colitis. Gastroenterology 2013; 145(4): 842 – 852.e2. doi: 10.1053/ j.gastro.2013.07.001.
12. Xiao YT, Wang J, Lu W et al. Downregulated expression of microRNA-124 in pediatric intestinal failure patients modulates macrophages activation by inhibiting STAT3 and AChE. Cell Death Dis 2016; 7(12): e2521. doi: 10.1038/ cddis.2016.426.
13. Vermeire S, Solitano V, Peyrin-Biroulet L et al. Obefazimod: a first-in-class drug for the treatment of ulcerative colitis. J Crohns Colitis 2023; 17(10): 1689 – 1697. doi: 10.1093/ ecco-jcc/ jjad067.
14. Apolit C, Campos N, Vautrin A et al. ABX464 (obefazimod) upregulates miR-124 to reduce proinflammatory markers in inflammatory bowel diseases. Clin Transl Gastroenterol 2023; 14(4): e00560. doi: 10.14309/ ctg.0000000000 000560.
15. Nagai-Singer MA, Morrison HA, Allen IC. NLRX1 is a multifaceted and enigmatic regulator of immune system function. Front Immunol 2019; 10 : 2419. doi: 10.3389/ fimmu.2019.02419.
16. Leber A, Hontecillas R, Zoccoli-Rodriguez V et al. Activation of NLRX1 by NX-13 alleviates inflammatory bowel disease through immunometabolic mechanisms in CD4+ T cells. J Immunol 2019; 203(12): 3407 – 3415. doi: 10.4049/ jimmunol.1900364.
17. Leber A, Hontecillas R, Tubau-Juni N et al. NLRX1 regulates effector and metabolic functions of CD4+ T cells. J Immunol 2017; 198(6): 2260 – 2268. doi: 10.4049/ jimmunol.1601547.
18. Verstockt B, Vermeire S, Peyrin-Biroulet L et al. The safety, tolerability, pharmacokinetics, and clinical efficacy of the NLRX1 agonist NX-13 in active ulcerative colitis: results of a phase 1b study. J Crohns Colitis 2024; 18(5): 762 – 772. doi: 10.1093/ ecco-jcc/ jjad192.
19. Garcia-Carbonell R, Yao SJ, Das S et al. Dysregulation of intestinal epithelial cell RIPK pathways promotes chronic inflammation in the IBD gut. Front Immunol 2019; 10 : 1094. doi: 10.3389/ fimmu.2019.01094.
20. Degterev A, Ofengeim D, Yuan J. Targeting RIPK1 for the treatment of human diseases. Proc Natl Acad Sci U S A 2019; 116(20): 9714 – 9722. doi: 10.1073/ pnas.1901179116.
21. Panayotova E, Atanassova A. P043 RIPK3 – a new marker for assessment of activity in Crohn’s disease. J Crohns Colitis 2024; 18(Suppl 1): i301. doi: 10.1093/ ecco-jcc/ jjad212.0173.
22. Weisel K, Scott N, Berger S et al. A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis. BMJ Open Gastroenterol 2021; 8(1): e000680. doi: 10.1136/ bmjgast-2021-000680.
23. Andoh A, Nishida A. Pro - and anti-inflammatory roles of interleukin (IL)-33, IL-36, and IL-38 in inflammatory bowel disease. J Gastroenterol 2023; 58(2): 69 – 78. doi: 10.1007/ s00535-
022-01936-x.
24. Nishida A, Hidaka K, Kanda T et al. Increased expression of interleukin-36, a member of the interleukin-1 cytokine family, in inflammatory bowel disease. Inflamm Bowel Dis 2016; 22(2): 303 – 314. doi: 10.1097/ MIB.0000000000000654.
25. Ferrante M, Irving PM, Selinger CP et al. Safety and tolerability of spesolimab in patients with ulcerative colitis. Expert Opin Drug Saf 2023; 22(2): 141 – 152. doi: 10.1080/ 14740338.2022.2103536.
26. Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol 2014; 6(10): a016295. doi: 10.1101/ cshperspect.a016295.
27. Rose-John S, Jenkins BJ, Garbers C et al. Targeting IL-6 trans-signalling: past, present and future prospects. Nat Rev Immunol 2023; 23(10): 666 – 681. doi: 10.1038/ s41577-023-00856-y.
28. Jostock T, Müllberg J, Ozbek S et al. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem 2001; 268(1): 160 – 167. doi: 10.1046/ j.1432-1327.2001.01867.x.
29. Schreiber S, Aden K, Bernardes JP et al. Therapeutic interleukin-6 trans-signaling inhibition by olamkicept (sgp130Fc) in patients with active inflammatory bowel disease. Gastroenterology 2021; 160(7): 2354 – 2366. doi: 10.1053/ j.gastro.2021.02.062.
30. Danese S, Neurath MF, Kopoń A et al. Effects of apremilast, an oral inhibitor of phosphodiesterase 4, in a randomized trial of patients with active ulcerative colitis. Clin Gastroenterol Hepatol 2020; 18(11): 2526 – 2534.e9. doi: 10.1016/ j.cgh.2019.12.032.
31. Mun Y, Kim W, Shin D. Melanocortin 1 receptor (MC1R): pharmacological and therapeutic aspects. Int J Mol Sci 2023; 24(15): 12152. doi: 10.3390/ ijms241512152.
32. Dodd J, Jordan R, Makhlina M et al. A novel oral formulation of the melanocortin-1 receptor agonist PL8177 resolves inflammation in preclinical studies of inflammatory bowel disease and is gut restricted in rats, dogs, and humans. Front Immunol 2023; 14 : 1083333. doi: 10.3389/ fimmu.2023.1083333.
33. Scarpa M, Kessler S, Sadler T et al. The epithelial danger signal IL-1a is a potent activator of fibroblasts and reactivator of intestinal inflammation. Am J Pathol 2015; 185(6): 1624 – 1637. doi: 10.1016/ j.ajpath.2015.02.018.
34. Aggeletopoulou I, Kalafateli M, Tsounis EP et al. Exploring the role of IL-1b in inflammatory bowel disease pathogenesis. Front Med (Lausanne) 2024; 11 : 1307394. doi: 10.3389/ fmed. 2024.1307394.
35. West NR, Hegazy AN, Owens BMJ et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat Med 2017; 23(5): 579 – 589. doi: 10.1038/ nm.4307.
36. Kokkotis G, Filidou E, Tarapatzi G et al. Oncostatin M induces a pro-inflammatory phenotype in intestinal subepithelial myofibroblasts. Inflamm Bowel Dis 2024; 30(11): 2162 – 2173. doi: 10.1093/ ibd/ izae098.
37. Guo A, Ross C, Chande N et al. High oncostatin M predicts lack of clinical remission for patients with inflammatory bowel disease on tumor necrosis factor a antagonists. Sci Rep 2022; 12(1): 1185. doi: 10.1038/ s41598-022-05208-9.
38. Hermanns HM. Oncostatin M and interleukin-31: cytokines, receptors, signal transduction and physiology. Cytokine Growth Factor Rev 2015; 26(5): 545 – 558. doi: 10.1016/
j.cytogfr.2015.07.006.
39. Yang Y, Wang L, Zeng Z et al. Gain-of-function variant in spleen tyrosine kinase regulates macrophage migration and functions to promote intestinal inflammation. J Inflamm Res 2024; 17 : 8713 – 8726. doi: 10.2147/ JIR.S
488901.
40. Aksentijevich I. The sickening consequences of too much SYK signaling. Nat Genet 2021; 53(4): 432 – 434. doi: 10.1038/ s41588-021-00837-8.
41. Chen RY, Zhu Y, Shen YY et al. The role of PD-1 signaling in health and immune-related diseases. Front Immunol 2023; 14 : 1163633. doi: 10.3389/ fimmu.2023.1163633.
42. Ghosh C, Luong G, Sun Y. A snapshot of the PD-1/ PD-L1 pathway. J Cancer 2021; 12(9): 2735 – 2746. doi: 10.7150/ jca.57334.
43. Yoshida T, Jiang F, Honjo T et al. PD-1 deficiency reveals various tissue-specific autoimmunity by H-2b and dose-dependent requirement of H-2g7 for diabetes in NOD mice. Proc Natl Acad Sci U S A 2008; 105(9): 3533 – 3538. doi: 10.1073/ pnas.0710951105.
44. Abu-Sbeih H, Faleck DM, Ricciuti B et al. Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease. J Clin Oncol 2020; 38(6): 576 – 583. doi: 10.1200/ JCO.19.01674.
45. Kim MK, Jo SI, Kim SY et al. PD-1-positive cells contribute to the diagnosis of inflammatory bowel disease and can aid in predicting response to vedolizumab. Sci Rep 2023; 13(1): 21329. doi: 10.1038/ s41598-023-48651-y.
46. Luu K, Dahl M, Hare E et al. DOP81 rosnilimab, a novel PD-1 agonist monoclonal antibody, reduces T cell proliferation, inflammatory cytokine secretion, and PD-1high expressing CD4 and CD8 T cells: results from a Phase 1 healthy volunteer clinical trial. J Crohns Colitis 2025; 18(Suppl 1): i225. doi: 10.1093/ ecco-jcc/ jjad212.0121.
47. Salmenkari H, Korpela R, Vapaatalo H. Renin-angiotensin system in intestinal inflammation-angiotensin inhibitors to treat inflammatory bowel diseases? Basic Clin Pharmacol Toxicol 2021; 129(3): 161 – 172. doi: 10.1111/ bcpt.13624.
48. Shi Y, Liu T, He L et al. Activation of the renin-angiotensin system promotes colitis development. Sci Rep 2016; 6 : 27552. doi: 10.1038/ srep 27552.
49. Jacobs JD, Wagner T, Gulotta G et al. Impact of angiotensin II signaling blockade on clinical outcomes in patients with inflammatory bowel disease. Dig Dis Sci 2019; 64(7): 1938 – 1944. doi: 10.1007/ s10620-019-5474-4.
50. Liu W, Wang L, Muefong C et al. SPH3127 (sitokiren), a novel renin inhibitor, suppresses colitis development in mouse models of experimental colitis. Inflamm Bowel Dis 2025; 31(8): 2244 – 2253. doi: 10.1093/ ibd/ izaf097.
51. Sitaru S, Budke A, Bertini R et al. Therapeutic inhibition of CXCR1/ 2: where do we stand? Intern Emerg Med 2023; 18(6): 1647 – 1664. doi: 10.1007/ s11739-023-03309-5.
52. Xv Y, Feng Y, Lin J. CXCR1 and CXCR2 are potential neutrophil extracellular trap-related treatment targets in ulcerative colitis: insights from Mendelian randomization, colocalization and transcriptomic analysis. Front Immunol 2024; 15 : 1425363. doi: 10.3389/ fimmu.2024.1425363.
53. Boyles JS, Beidler CB, Strifler BA et al. Discovery and characterization of a neutralizing pan-ELR+CXC chemokine monoclonal antibody. MAbs 2020; 12(1): 1831880. doi: 10.1080/ 19420862.2020.1831880.
54. Tinoco R, Otero DC, Takahashi AA et al.
PSGL-1: a new player in the immune checkpoint landscape. Trends Immunol 2017; 38(5): 323 – 335. doi: 10.1016/ j.it.2017.02.002.
55. Hope JL, Otero DC, Bae EA et al. PSGL-1 attenuates early TCR signaling to suppress CD8+ T cell progenitor differentiation and elicit terminal CD8+ T cell exhaustion. Cell Rep 2023; 42(5): 112436. doi: 10.1016/ j.celrep.2023.
112436.
56. Huang CC, Lu YF, Wen SN et al. A novel apoptosis-inducing anti-PSGL-1 antibody for T cell-mediated diseases. Eur J Immunol 2005; 35(7): 2239 – 2249. doi: 10.1002/ eji.200525849.
57. Lovewell RR, Langermann S, Flies DB. Immune inhibitory receptor agonist therapeutics. Front Immunol 2025; 16 : 1566869. doi: 10.3389/ fimmu.2025.1566869.
58. Chen Y, Ye X, Escames G et al. The NLRP3 inflammasome: contributions to inflammation-related diseases. Cell Mol Biol Lett 2023; 28(1): 51. doi: 10.1186/ s11658-023-00462-9.
59. Weber S, Sitte S, Voegele A et al. NLRP3 inhibition leads to impaired mucosal fibroblast function in patients with inflammatory bowel diseases, J Crohns Colitis 2024; 18(3): 446 – 461. doi: 10.1093/ ecco-jcc/ jjad164.
60. Liu L, Dong Y, Ye M et al. The pathogenic role of NLRP3 inflammasome activation in inflammatory bowel diseases of both mice and humans. J Crohns Colitis 2017; 11(6): 737 – 750. doi: 10.1093/ ecco-jcc/ jjw219.
61. Parmar DV, Kansagra KA, Momin T et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral NLRP3 inflammasome inhibitor ZYIL1: first-in-human phase 1 studies (single ascending dose and multiple ascending dose). Clin Pharmacol Drug Dev 2023; 12(2): 202 – 211. doi: 10.1002/ cpdd.1162.
62. Watson N, Kuppuswamy S, Ledford WL et al. The role of HDAC3 in inflammation: mechanisms and therapeutic implications. Front Immunol 2024; 15 : 1419685. doi: 10.3389/ fimmu. 2024.1419685.
63. Li C, Gu S, Zhang Y et al. Histone deacetylase in inflammatory bowel disease: novel insights. Therap Adv Gastroenterol 2025; 18 : 17562848251318833. doi: 10.1177/ 1756284 8251318833.
64. Graßhoff H, Comdühr S, Monne LR et al. Low-dose IL-2 therapy in autoimmune and rheumatic diseases. Front Immunol 2021; 12 : 648408. doi: 10.3389/ fimmu.2021.648408.
65. Ko B, Takebe N, Andrews O et al. Rethinking oncologic treatment strategies with interleukin-2. Cells 2023; 12(9): 1316. doi: 10.3390/ cells12091316.
66. Rosenzwajg M, Lorenzon R, Cacoub P et al. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Ann Rheum Dis 2019; 78(2): 209 – 217. doi: 10.1136/ annrheumdis-2018-214229.
67. Allegretti JR, Mitsialis V, Canavan JB et al. Low-dose interleukin 2 for the treatment of moderate to severe ulcerative colitis. Gastroenterology 2023; 165(2): 492 – 495. doi: 10.1053/ j.gastro.2023.03.230.
68. Deng Z, Fan T, Xiao C et al. TGF-b signaling in health, disease, and therapeutics. Signal Transduct Target Ther 2024; 9(1): 61. doi: 10.1038/ s41392-024-01764-w.
69. Peng D, Fu M, Wang M et al. Targeting TGF-b signal transduction for fibrosis and cancer therapy. Mol Cancer 2022; 21(1): 104. doi: 10.1186/ s12943-022-01569-x.
70. Bertin L, Crepaldi M, Zanconato M et al. Advancing therapeutic frontiers: a pipeline of novel drugs for luminal and perianal Crohn‘s disease management. Therap Adv Gastroenterol 2024; 17 : 17562848241303651. doi: 10.1177/ 17562848241303651.
71. Wu X, Sun M, Yang Z et al. The roles of CCR9/ CCL25 in inflammation and inflammation-associated diseases. Front Cell Dev Biol 2021; 9 : 686548. doi: 10.3389/ fcell.2021.686548.
72. Wendt E, Keshav S. CCR9 antagonism: potential in the treatment of inflammatory bowel disease. Clin Exp Gastroenterol 2015; 8 : 119 – 130. doi: 10.2147/ CEG.S48305.
73. Kalindjian SB, Kadnur SV, Hewson CA et al. A new series of orally bioavailable chemokine receptor 9 (CCR9) antagonists; possible agents for the treatment of inflammatory bowel disease. J Med Chem 2016; 59(7): 3098 – 3111. doi: 10.1021/ acs.jmedchem.5b01840.
74. Hedin CR, Creignou M, MacKay J et al. P1116 imaging of CCR9 in the small bowel of patients with Crohn’s disease: effects of the CCR9-depleting monoclonal antibody AZD7798. J Crohns Colitis 2025; (Suppl 1): i2048 – i2049.
Labels
Paediatric gastroenterology Gastroenterology and hepatology SurgeryArticle was published in
Gastroenterology and Hepatology
2026 Issue 2
- The Importance of Limosilactobacillus reuteri in Administration to Diabetics with Gingivitis
- Safety and Tolerance of Metamizole in Postoperative Analgesia in Children
- Metamizole in perioperative treatment in children under 14 years – results of a questionnaire survey from practice
- Obstacle Called Vasospasm: Which Solution Is Most Effective in Microsurgery and How to Pharmacologically Assist It?
Most read in this issue
- Benefits and risks of HCV cure
- Diagnosis and therapy of hepatitis B virus infection: Czech national guidelines
- Mapování horizontu léčby ulcerózní kolitidy v éře inhibitorů IL-23
- Neutrophil-to-lymphocyte ratio refl ects infl ammatory phenotypes of alcohol-associated hepatitis: diff erences between mild and severe dis ease